<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234842</url>
  </required_header>
  <id_info>
    <org_study_id>UFPTI 1605-ES01</org_study_id>
    <nct_id>NCT03234842</nct_id>
  </id_info>
  <brief_title>Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer</brief_title>
  <acronym>ES01</acronym>
  <official_title>A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if proton beam therapy as part of chemoradiation results in a
      decrease in diffusion lung capacity of carbon monoxide (DLCO) compared to photon radiation
      therapy for esophageal carcinoma. A secondary objective is to determine effects on cardiac
      function, quality of life, and compare acute and late toxicities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation Modality: Proton radiotherapy will be offered to all patients that meet trial
      eligibility. If patients decline proton radiotherapy or are otherwise unable to receive
      proton therapy they will be included in x-ray cohort (group 2).

      Chemotherapy will be delivered at the discretion of the treating Medical Oncologist. Weekly
      carboplatin and paclitaxel at standard doses is preferred. It is recommended that the weekly
      chemotherapy regimen be continued throughout the course of radiotherapy. Chemotherapy should
      begin within 48 hours of beginning radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">December 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of a clinically significant reduction of DLCO (defined as a decrease of â‰¥ 10% from baseline) between protons and photons after preoperative or definitive chemoradiation</measure>
    <time_frame>Approximately 12 months after radiation therapy</time_frame>
    <description>Participants with a clinically significant reduction of DLCO approximately 12 months after radiation therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life</measure>
    <time_frame>Approximately 12 months after radiation therapy</time_frame>
    <description>Participants quality of life results using EORTC Quality of Life Questionnaire - Oesophageal Cancer Module (OES-18) and EORTC QLQ C-30 conjointly approximately 12 months after radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare outcomes for local control</measure>
    <time_frame>Approximately 12 months after radiation therapy</time_frame>
    <description>Number of participants with local control for proton and photon radiation and concurrent chemotherapy as part of definitive therapy or trimodality therapy approximately 12 months after radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare outcomes for progression free survival</measure>
    <time_frame>Approximately 12 months after radiation therapy</time_frame>
    <description>Number of participants with progression free survival for proton and photon radiation and concurrent chemotherapy as part of definitive therapy or trimodality therapy approximately 12 months after radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival rates</measure>
    <time_frame>Approximately 12 months after radiation therapy</time_frame>
    <description>Number of participants with overall survival rates for proton and photon radiation and concurrent chemotherapy as part of definitive therapy or trimodality therapy approximately 12 months after radiation therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Therapy</intervention_name>
    <description>59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses</description>
    <arm_group_label>Proton</arm_group_label>
    <other_name>Proton Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon Radiation Therapy</intervention_name>
    <description>59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses</description>
    <arm_group_label>Photon</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Concurrent weekly chemotherapy at standard doses</description>
    <arm_group_label>Proton</arm_group_label>
    <arm_group_label>Photon</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years at the time of consent.

          -  Pathologically confirmed esophageal adenocarcinoma or squamous cell. carcinoma of the
             thoracic esophagus or esophagogastric junction.

          -  Patient's preliminary cancer stage, according to the AJCC 7th edition staging, must be
             cT1b-T4, N0-N3.

        Exclusion Criteria:

          -  Patients with cervical esophageal carcinoma.

          -  Prior radiotherapy with fields overlapping the current esophageal cancer.

          -  Patients with cT1a disease.

          -  Patients with evidence of tracheoesophageal fistula must undergo bronchoscopy to
             exclude fistula.

          -  Patients with distant metastatic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Rutenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UF Health Proton Therapy Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Intake Coordinator</last_name>
    <phone>877-686-6009</phone>
    <email>intake@floridaproton.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Ward</last_name>
    <phone>877-686-6009</phone>
    <email>lward@floridaproton.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake Coordinator</last_name>
      <phone>877-686-6009</phone>
      <email>intake@floridaproton.org</email>
    </contact>
    <investigator>
      <last_name>Michael Rutenberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.</citation>
    <PMID>26742998</PMID>
  </reference>
  <reference>
    <citation>Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996 Aug 15;335(7):462-7. Erratum in: N Engl J Med 1999 Jul 29;341(5):384.</citation>
    <PMID>8672151</PMID>
  </reference>
  <reference>
    <citation>van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.</citation>
    <PMID>22646630</PMID>
  </reference>
  <reference>
    <citation>Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. doi: 10.1200/JCO.2007.12.9593.</citation>
    <PMID>18309943</PMID>
  </reference>
  <reference>
    <citation>Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005 Apr 1;23(10):2310-7. Erratum in: J Clin Oncol. 2006 Jan 20;24(3):531.</citation>
    <PMID>15800321</PMID>
  </reference>
  <reference>
    <citation>Bedenne L, Michel P, BouchÃ© O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8.</citation>
    <PMID>17401004</PMID>
  </reference>
  <reference>
    <citation>Gergel TJ, Leichman L, Nava HR, Blumenson LE, Loewen GM, Gibbs JE, Khushalani NI, Leichman CG, Bodnar LM, Douglass HO, Smith JL, Kuettel MR, Proulx GM. Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis. Cancer J. 2002 Nov-Dec;8(6):451-60.</citation>
    <PMID>12500854</PMID>
  </reference>
  <reference>
    <citation>von DÃ¶beln GA, Nilsson M, Adell G, Johnsen G, Hatlevoll I, Tsai J, Lundell L, Lund M, Lind P. Pulmonary function and cardiac stress test after multimodality treatment of esophageal cancer. Pract Radiat Oncol. 2016 May-Jun;6(3):e53-9. doi: 10.1016/j.prro.2015.10.015. Epub 2015 Nov 10.</citation>
    <PMID>26725962</PMID>
  </reference>
  <reference>
    <citation>Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB Jr, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1317-22.</citation>
    <PMID>14630268</PMID>
  </reference>
  <reference>
    <citation>Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):885-91. doi: 10.1016/j.ijrobp.2013.04.006.</citation>
    <PMID>23845841</PMID>
  </reference>
  <reference>
    <citation>Lund M, Alexandersson von DÃ¶beln G, Nilsson M, Winter R, Lundell L, Tsai JA, Kalman S. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial. Radiat Oncol. 2015 Jan 13;10:16. doi: 10.1186/s13014-014-0310-7.</citation>
    <PMID>25582305</PMID>
  </reference>
  <reference>
    <citation>De Jaeger K, Seppenwoolde Y, Boersma LJ, Muller SH, Baas P, Belderbos JS, Lebesque JV. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1331-40.</citation>
    <PMID>12654445</PMID>
  </reference>
  <reference>
    <citation>Marks LB, Fan M, Clough R, Munley M, Bentel G, Coleman RE, Jaszczak R, Hollis D, Anscher M. Radiation-induced pulmonary injury: symptomatic versus subclinical endpoints. Int J Radiat Biol. 2000 Apr;76(4):469-75.</citation>
    <PMID>10815626</PMID>
  </reference>
  <reference>
    <citation>Lopez Guerra JL, Gomez DR, Zhuang Y, Levy LB, Eapen G, Liu H, Mohan R, Komaki R, Cox JD, Liao Z. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e537-43. doi: 10.1016/j.ijrobp.2012.01.019. Epub 2012 Mar 13.</citation>
    <PMID>22420964</PMID>
  </reference>
  <reference>
    <citation>Miller KL, Zhou SM, Barrier RC Jr, Shafman T, Folz RJ, Clough RW, Marks LB. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):611-5.</citation>
    <PMID>12788165</PMID>
  </reference>
  <reference>
    <citation>Enache I, Noel G, Jeung MY, Meyer N, Oswald-Mammosser M, Pistea C, Jung GM, Mennecier B, Quoix E, Charloux A. Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: a prospective study. Respiration. 2013;86(2):100-8. doi: 10.1159/000342371. Epub 2012 Nov 13.</citation>
    <PMID>23154264</PMID>
  </reference>
  <reference>
    <citation>Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):639-44.</citation>
    <PMID>15936539</PMID>
  </reference>
  <reference>
    <citation>Ferguson MK, Celauro AD, Prachand V. Prediction of major pulmonary complications after esophagectomy. Ann Thorac Surg. 2011 May;91(5):1494-1500; discussion 1500-1. doi: 10.1016/j.athoracsur.2010.12.036.</citation>
    <PMID>21524462</PMID>
  </reference>
  <reference>
    <citation>Ferguson MK, Durkin AE. Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2002 Apr;123(4):661-9.</citation>
    <PMID>11986593</PMID>
  </reference>
  <reference>
    <citation>Lin FC, Durkin AE, Ferguson MK. Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg. 2004 Nov;78(5):1783-9. Review.</citation>
    <PMID>15511475</PMID>
  </reference>
  <reference>
    <citation>Cerfolio RJ, Talati A, Bryant AS. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications. Ann Thorac Surg. 2009 Sep;88(3):930-5; discussion 935-6. doi: 10.1016/j.athoracsur.2009.06.013.</citation>
    <PMID>19699923</PMID>
  </reference>
  <reference>
    <citation>Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . J Clin Oncol. 1992 Jul;10(7):1037-43. Erratum in: J Clin Oncol 1992 Nov;10(11):1822.</citation>
    <PMID>1607911</PMID>
  </reference>
  <reference>
    <citation>Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 1;103(7):1347-55.</citation>
    <PMID>15719440</PMID>
  </reference>
  <reference>
    <citation>Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010 Apr;17(4):1159-67. doi: 10.1245/s10434-009-0862-1. Epub 2010 Feb 6.</citation>
    <PMID>20140529</PMID>
  </reference>
  <reference>
    <citation>Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009 Feb;87(2):392-8; discussion 398-9. doi: 10.1016/j.athoracsur.2008.11.001.</citation>
    <PMID>19161745</PMID>
  </reference>
  <reference>
    <citation>Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997 Jul 17;337(3):161-7.</citation>
    <PMID>9219702</PMID>
  </reference>
  <reference>
    <citation>Yoon DH, Jang G, Kim JH, Kim YH, Kim JY, Kim HR, Jung HY, Lee GH, Song HY, Cho KJ, Ryu JS, Kim SB. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):489-96. doi: 10.1016/j.ijrobp.2014.11.019. Epub 2015 Jan 30.</citation>
    <PMID>25680595</PMID>
  </reference>
  <reference>
    <citation>Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.</citation>
    <PMID>20351330</PMID>
  </reference>
  <reference>
    <citation>Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.</citation>
    <PMID>23975663</PMID>
  </reference>
  <reference>
    <citation>Venkat P, Shridhar R, Naghavi A, et al. Pathologic Complete Response and Dose Escalation with Preoperative Dose Painting IMRT Chemoradiation in Esophageal Cancer. IJROBP. 2015; 93:S219-220</citation>
  </reference>
  <reference>
    <citation>Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, Mizumoto M, Okumura T, Sakae T, Sakurai H. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res. 2015 May;56(3):568-76. doi: 10.1093/jrr/rrv001. Epub 2015 Mar 9.</citation>
    <PMID>25755255</PMID>
  </reference>
  <reference>
    <citation>Wang J, Palmer M, Bilton SD, et al. Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer. Int J Particle Ther. 2015;1:866-877.</citation>
  </reference>
  <reference>
    <citation>Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):692-9. Epub 2005 Oct 19.</citation>
    <PMID>16242257</PMID>
  </reference>
  <reference>
    <citation>Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, Komaki R, Liao Z. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):707-14. doi: 10.1016/j.ijrobp.2007.10.056. Epub 2008 Jan 11.</citation>
    <PMID>18191334</PMID>
  </reference>
  <reference>
    <citation>Donohoe CL, McGillycuddy E, Reynolds JV. Long-term health-related quality of life for disease-free esophageal cancer patients. World J Surg. 2011 Aug;35(8):1853-60. doi: 10.1007/s00268-011-1123-6.</citation>
    <PMID>21553202</PMID>
  </reference>
  <reference>
    <citation>Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, Arraras J, Bottomley A, Vickery CW, Etienne PL, Alderson D; European Organisation for Research and Treatement of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003 Jul;39(10):1384-94.</citation>
    <PMID>12826041</PMID>
  </reference>
  <reference>
    <citation>Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol. 2012 Feb 1;30(4):413-8. doi: 10.1200/JCO.2011.38.9791. Epub 2012 Jan 3.</citation>
    <PMID>22215745</PMID>
  </reference>
  <reference>
    <citation>Hurmuzlu M, Aarstad HJ, Aarstad AK, Hjermstad MJ, Viste A. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. Dis Esophagus. 2011 Jan;24(1):39-47. doi: 10.1111/j.1442-2050.2010.01104.x. Epub 2010 Sep 2.</citation>
    <PMID>20819100</PMID>
  </reference>
  <reference>
    <citation>Kachnic LA, Winter K, Wasserman T, Kelsen D, Ginsberg R, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Willett CG, Minsky BD. Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res. 2011 Mar;4(2):45-52.</citation>
    <PMID>21673875</PMID>
  </reference>
  <reference>
    <citation>Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):423-9. doi: 10.1016/j.ijrobp.2014.06.028.</citation>
    <PMID>25304796</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagus</keyword>
  <keyword>Proton</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

